BioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $8.00 Price Target at Barclays

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price lifted by Barclays from $7.00 to $8.00 in a report issued on Tuesday morning, Benzinga reports. They currently have an equal weight rating on the biotechnology company’s stock.

BCRX has been the topic of several other reports. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. JMP Securities raised their price objective on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.67.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $7.06 on Tuesday. The stock has a 50 day moving average price of $7.82 and a 200 day moving average price of $6.97. The stock has a market capitalization of $1.46 billion, a PE ratio of -11.57 and a beta of 1.89. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). The company had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. During the same quarter in the prior year, the company earned ($0.19) EPS. The company’s revenue for the quarter was up 35.1% on a year-over-year basis. As a group, research analysts forecast that BioCryst Pharmaceuticals will post -0.37 EPS for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. CWM LLC grew its holdings in BioCryst Pharmaceuticals by 200.0% in the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 3,772 shares in the last quarter. Signaturefd LLC raised its stake in BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,599 shares in the last quarter. Seven Eight Capital LP acquired a new stake in BioCryst Pharmaceuticals in the 1st quarter worth about $57,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares during the period. Finally, Natixis grew its position in shares of BioCryst Pharmaceuticals by 400.6% during the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 9,350 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.